Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Aug;12(4):601-607.
doi: 10.1007/s40744-025-00773-7. Epub 2025 Jun 15.

Safety of Accelerated Rituximab Infusion in Rheumatic Diseases: A Systematic Review

Jozélio Freire de Carvalho  1 , Samuel de Oliveira Andrade  2 , Ana Tereza Amoedo Martinez  3 , Thelma Skare  4 , Simone Appenzeller  5
Affiliations
Editorial

Safety of Accelerated Rituximab Infusion in Rheumatic Diseases: A Systematic Review

Jozélio Freire de Carvalho et al. Rheumatol Ther. 2025 Aug.

Abstract

Objective: To systematically evaluate the safety and feasibility of rapid rituximab (RTX) infusion protocols in patients with autoimmune rheumatic diseases.

Methods: A comprehensive literature review was conducted using PubMed, LILACS, and Scielo databases from 1965 to May 2024 without language restrictions. Studies reporting infusion reactions associated with accelerated RTX protocols (infusion over 90 to 120 min) in rheumatologic conditions were included. Infusion-related adverse events were assessed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (Grades 1-5). Key variables extracted included patient demographics, underlying diseases, RTX dosage, use of premedication, number of infusions, and frequency and severity of infusion reactions.

Results: Seven studies encompassing 538 patients aged 14-78 years were included. The patient cohort covered a spectrum of autoimmune rheumatic conditions, including systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, Sjögren's syndrome, systemic sclerosis, IgG4-related disease, and anti-synthetase syndrome. All studies implemented rapid RTX infusion protocols exclusively for the second and subsequent doses. Premedication with acetaminophen, diphenhydramine, and corticosteroids was routine in most studies. RTX dosage varied between 375 mg/m2 and 1000 mg, administered in two infusions spaced two weeks apart. The incidence of infusion reactions ranged from 3 to 15%, predominantly of mild severity (Grades 1 and 2), with only six cases classified as Grade 3. No Grade 4 or 5 reactions were reported. Rapid infusion protocols consistently reduced the total time patients spent in infusion clinics.

Conclusion: Rapid infusion of RTX in patients with autoimmune rheumatic diseases appears to be a safe and efficient alternative to standard infusion protocols. The frequency and severity of infusion reactions were comparable to traditional infusion rates, with the added benefit of reduced clinic time. These findings support the broader implementation of rapid infusion protocols in rheumatology. However, larger prospective studies with standardized reporting of adverse events are necessary to validate these results and explore the feasibility of even shorter infusion durations, as seen in oncology.

Keywords: Biological therapy; Infusion reaction; Rapid infusion; Rheumatic diseases; Rituximab.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of Interest: Jozelio Freire de Carvalho is an Editorial Board member of Rheumatology Therapy, he was not involved in selecting peer reviewers for the manuscript or any subsequent editorial decisions. Samuel de Oliveira Andrade has nothing to disclosure. Ana Teresa Amoedo Martinez has nothing to disclosure. Thelma Skare has nothing to disclosure. Simone Appenzeller has nothing to disclosure. Ethical Approval: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

References

    1. de Carvalho JF, Dos Santos MNP, de Oliveira JMV, Lanty Silva ANS, de Araujo RPC, Cardozo JB. Evaluation of the safety and satisfaction of rheumatic patients with accelerated infliximab infusion. Adv Rheumatol. 2018;58(1):22. - PubMed
    1. Accessed at webpage: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103705s5367s53...
    1. Swan JT, Zaghloul HA, Cox JE, Murillo JR Jr. Use of a pharmacy protocol to convert standard rituximab infusions to rapid infusion shortens outpatient infusion clinic visits. Pharmacotherapy. 2014;34(7):686–94. - PubMed
    1. Moore DC, Gebru T, Plesca D. Evaluation of a pharmacist-driven rapid infusion rituximab conversion protocol at a multisite cancer center. J Oncol Pharm Pract. 2021;27(8):1914–8. - PubMed
    1. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Version 4.0. Published June 14, 2010.

Publication types

LinkOut - more resources